NASDAQ · Biotechnology · USD
CNS Pharmaceuticals, Inc. (CNSP) Stock Analysis
CNS Pharmaceuticals, Inc. (CNSP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CNSP Key Statistics
As of Oct 21, 2026Trading
- Open
- $4.83
- Previous Close
- $4.99
- 52-Week Range
- 1.90–10.54
- Volume
- 346.00
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.02
Valuation
- Market Cap
- $7.29M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −17.90
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$15.85M
- Shares Outstanding
- 1.46M
- 1-Year Return
- −46.39%
Dividend and dates
- Avg Volume
- 6.27K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CNSP closed at $4.83, −46.39% over 1 year.
CNS Pharmaceuticals, Inc. (CNSP) has a market capitalization of $7.29M.
In fiscal 2025, CNSP reported revenue of $0.00.
CNSP Stock Return by Calendar Year
CNS Pharmaceuticals, Inc. (CNSP) return since Nov 2019: what $10,000 became
- 1 year
- $10,000 $5,361
- −46.39%
- 5 years
- $10,000 $0.04
- −99.9996%
- Since Nov 2019
- $10,000 $0.01
- −99.9999%
If you had invested $10,000 in CNS Pharmaceuticals, Inc. (CNSP) at the close on November 8, 2019, the earliest close on record here, it would have been worth $0.01 at the close on October 21, 2026: −99.9999% in total, −85.98% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −8.10% |
| 2025 | −92.71% |
| 2024 | −99.81% |
| 2023 | −47.08% |
| 2022 | −88.60% |
| 2021 | −60.56% |
| 2020 | −54.94% |
| 2019 (partial year) | −13.57% |
As of October 21, 2026.
CNSP Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$15.85M | — |
| 2024 | $0.00 | −$14.86M | — |
| 2023 | $0.00 | −$18.85M | — |
| 2022 | $0.00 | −$15.27M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$15.99M | −$15.85M | — |
| 2024 | $0.00 | — | −$14.90M | −$14.86M | — |
| 2023 | $0.00 | — | −$18.87M | −$18.85M | — |
| 2022 | $0.00 | — | −$15.27M | −$15.27M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript
SeekingAlphaCNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
YahooCNS Pharmaceuticals Q2 EPS $(0.38) Misses $(0.24) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B